BIIB : Analysis & Opinions

  1. Agenus Jumps on Positive Data from Shingles Candidate - Analyst ...

    December 19, 2014
    Shares of Agenus Inc. (AGEN) jumped after its partner GlaxoSmithKline (GSK) announced encouraging results on HZ/su.
  2. Integra Lifesciences Up on Launch of Bilayer Skin Product - ...

    December 19, 2014
    This latest single-use skin product of Integra (IART) is at present the only pre-meshed bilayer matrix that has been approved ...
  3. Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - ...

    December 19, 2014
    Seattle Genetics, Inc. (SGEN) has initiated a phase Ib study on SGN-CD33A for newly diagnosed acute myeloid leukemia.
  4. Bruker Unveils bioAFM System for High Resolution Imaging - Analyst ...

    December 18, 2014
    Bruker's (BRKR) BioScope Resolve provides real-time correlation of atomic force microscopy and optical microscopy data sets
  5. Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst ...

    December 16, 2014
    Alkermes (ALKS) announced the commencement of a phase I extended dosing study on aripiprazole lauroxil for the treatment ...
  6. Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit ...

    December 16, 2014
    Acorda (ACOR) has commenced a phase III study on Ampyra for the treatment of post-stroke walking deficits.
  7. Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst ...

    December 16, 2014
    On Dec 10, 2014, we issued an updated research report on Illumina Inc. (ILMN).
  8. Genomic Health's Breast Cancer Test Yields Positive Results - ...

    December 16, 2014
    Oncotype DX breast cancer test ??? as Genomic Health's (GHDX) first product ??? has been an important contributor to U.S. ...
  9. Stock Market News for December 16, 2014 - Market News

    December 16, 2014
    Markets finished a choppy session in the negative territory on Monday as yet another slide in oil prices dented investor ...
  10. Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst ...

    December 15, 2014
    Alexion (ALXN) announced that Soliris has received orphan drug designation in Japan for the treatment of myasthenia gravis.
  11. Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - ...

    December 15, 2014
    Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
  12. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  13. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  14. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  15. Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry.

    A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  16. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  17. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  18. Can Sanofi Investors Just Blame It On Rio?

    August 6, 2013
    Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi (NYSE: SNY) was supposed to be a relatively ...
  19. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  20. Glaxo Gets Offer for Thrombosis Drugs - Analyst Blog

    June 19, 2013
    GlaxoSmithKline announced that Aspen Pharmacare Holdings Limited has offered to buy Glaxo's thrombosis brands
  21. Perrigo in Expansion Mode - Analyst Blog

    June 18, 2013
    Perrigo has purchased Fera's eye-care portfolio.
  22. Elan Shareholders Bring Management To Heel

    June 17, 2013
    The rejection of Elan management's proposed transactions ought to accelerate the sale of the company.
  23. Bull of the Day: Biogen (BIIB) - Bull of the Day

    June 14, 2013
    Bull of the Day: Biogen (BIIB) - Bull of the Day
  24. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  25. 3 Impressive Biotech ETFs Crushing the Market - ETF News And ...

    June 11, 2013
    Rotate into the outperforming biotech sector with these three ETFs.
  26. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  27. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  28. ELN/BIIB Seek Label Expansion - Analyst Blog

    January 17, 2013
    Biogen Idec Inc. (BIIB) and partner Elan Corporation (ELN) recently submitted applications to the US Food and Drug Administration ...
  29. PDLI Guides Q4 Royalty Rev to $86M - Analyst Blog

    December 7, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate fourth quarter 2012 royalty revenues of $86 million, ...
  30. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  31. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  32. Biogen Idec - Momentum

    September 24, 2012
    Positive earnings estimate revisions, a strong second quarter and an upbeat guidance for 2012 helped Biogen Idec, Inc. (BIIB) ...
  33. Isis Pharma Stays Neutral - Analyst Blog

    July 11, 2012
    We recently reiterated our Neutral recommendation on Isis Pharmaceuticals (ISIS), which carries a Zacks #3 Rank (short-term ...
  34. Biotech ETFs Hitting Highs

    May 17, 2012
    Biotech ETFs are hitting all-time highs and XBI looks like the best of the group. Because the ETF is already up 25% in 2 ...
  35. Best S&P 500 Stocks Of 2011

    January 5, 2012
    The best performing stocks in the S & P 500 in 2011 were concentrated in the energy and health care sectors.
  36. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  37. 2011's Highest Performing S&P500 stocks

    December 15, 2011
    Check out 2011's highest-performing S&P 500 stocks.
  38. How to Use Technicals to Trade ETFs

    November 7, 2011
    A couple of health-care growth names are performing well after earnings, says Ken Shreve, who also shares his methodology ...
  39. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  40. Abbott Labs Joins The Separation Movement

    October 24, 2011
    Abbott is joining the separation movement that is sweeping across corporate America. The company plans to break into a medical ...
  41. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors. ...
  42. 6 Overbought Stocks To Watch

    April 25, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  43. Human Genome Takes A Big Step Forward

    November 17, 2010
    HGSI's prospects get a big boost from a panel approval.
  44. 4 Companies That Should Have Sold Out

    September 9, 2010
    When company management gets unreasonably stubborn and refuses a merger or buyout, shareholders often pay the price.
  45. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  46. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  47. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  48. 3 Great But Misunderstood Stocks

    May 4, 2010
    Is a lack of understanding of these 3 stocks causing some investors to miss the boat?
  49. Cash Rich, No Debt Stocks

    February 8, 2010
    Anytime you can find a company with lots of cash and little or no debt, it's worth a closer look.
  50. Is Now The Time To Buy Pharmaceuticals?

    May 5, 2009
    Despite the recession, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide. ...
Trading Center